Syros Pharmaceuticals ( (SYRS) ) has released its Q3 earnings. Here is a breakdown of the information Syros Pharmaceuticals presented to its investors.
Syros Pharmaceuticals, Inc., a biopharmaceutical company headquartered in Cambridge, Massachusetts, focuses on developing treatments for hematologic malignancies. In their latest earnings report for Q3 2024, Syros Pharmaceuticals reported a net loss of $6.4 million, a significant improvement from the $40.1 million loss in the same quarter last year. Despite the decrease in operating expenses, the company saw no revenue due to the termination of a collaboration agreement. Key financial metrics included a reduction in cash and cash equivalents from $139.5 million at year-end 2023 to $58.3 million as of September 2024. The company’s restructuring efforts, including a 35% workforce reduction, were implemented to prioritize the development of tamibarotene, a treatment for myelodysplastic syndrome and acute myeloid leukemia. Looking ahead, Syros Pharmaceuticals plans to focus on advancing tamibarotene and exploring additional financing options to support its operations.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
